ClinicalTrials.gg
CompletedNCT02859129ECLIPSEIIIUpdated Aug 17, 2016

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

A Phase 1 interventional study of rosuvastatin 40 mg tablet and Epanova™ QD (2 x 1 g capsules) in Hypertriglyceridemia, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Hypertriglyceridemia by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hypertriglyceridemia · AstraZeneca.

Enrollment
7th of 12
114 · median 224
Started
2013
with 1 other
Phase 1
4 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Hypertriglyceridemia by AstraZeneca, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 1, and was the 12th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

None of the 12 studies in Hypertriglyceridemia by AstraZeneca is open now. The open studies under Hypertriglyceridemia, anywhere →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Hypertriglyceridemia by AstraZeneca as a file.
02

Study summary

This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin

Read the detailed description

The PK of rosuvastatin will be monitored following single-dose administration of rosuvastatin with and without multiple-dose administration of 4 g Epanova™ for 13 consecutive days in order to detect a possible interaction between rosuvastatin and Epanova™. The PK of total EPA, total DHA and total EPA+DHA will also be monitored following multiple-dose administration of Epanova™ with and without single-dose administration of 40 mg rosuvastatin. A single dose administration for rosuvastatin has been judged sufficient to yield plasma concentrations that will be detectable with an adequate validated analytical method and characterize adequately the PK of rosuvastatin.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

Keywords

  • Epanova
  • omega-3 carboxylic acids
  • Vascepa
  • Eicosapentaenoic acid ethyl ester
  • Crestor
  • rosuvastatin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (non-)
  • (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening
  • Non-smoker
  • Medically healthy with no laboratory profiles, vital signs or ECGs

Exclusion criteria

Exclusion Criteria:

  • mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study
  • History or presence of myopathy and/or hypothyroidism.
  • History or presence of transaminase elevations
  • History or presence of or idiosyncratic reaction to rosuvastatin, to other HMG-CoA reductase inhibitors, to Epanova™, to Vascepa®, or to related compounds
  • Known sensitivity or allergy to soybeans, fish, and/or shellfish.
  • Has consumed fish within 7 days prior to check-in.
  • Female subjects who are pregnant or lactating.
  • Positive urine drug and alcohol results at screening or check-in.
  • Positive urine cotinine at screening and check-in
  • Use of any drugs known to be inducers of CYP enzymes and/or P-gp
  • Donation of blood or significant blood loss within 56 days prior to the first dose of study medication.
  • Plasma donation within 7 days prior to the first dose of study medication.
  • Participation in another clinical trial within 28 days prior to the first dose of study medication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Rosuvastatin

    Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).

    Drug: rosuvastatin 40 mg tablet

  • Experimental
    Epanova®

    Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)

    Drug: Epanova™ QD (2 x 1 g capsules)

  • Experimental
    Epanova® + Crestor®

    Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24

    Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose

  • Active comparator
    Vascepa®

    Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).

    Drug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours

Interventions

  • Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).

    Also known as: Crestor

  • Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)

    Also known as: omega-3 carboxylic acids

  • DrugMultiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose

    Drug page: Omega-3 carboxylic acid

    Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24

    Also known as: omega-3 carboxylic acids, Crestor

  • Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).

    Also known as: icosapent ethyl

06

What researchers measure

Primary outcomes

  1. ln-transformed Cmax,ss of baseline-adjusted total EPA, total DHA, and total EPA+DHA

    ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.

    Time frame: Days 1 and 24

  2. ln-transformed AUC0-tau of baseline-adjusted total EPA, total DHA, and total EPA+DHA

    ln-transformed AUC0-tau of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.

    Time frame: Days 1 and 24

Secondary outcomes

  1. ln-transformed Cmax,ss of unadjusted total EPA, total DHA, and total EPA+DHA

    ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.

    Time frame: Days 1 and 24

  2. dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g

    In Cohort 1 only, dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g using an analysis of variance (ANOVA) on dose normalized data.

    Time frame: Days 1 and 24

  3. ln-transformed AUC0-tau of unadjusted total EPA, total DHA, and total EPA+DHA

    ln-transformed AUC0-tau of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.

    Time frame: Days 1 and 24

Other outcomes

  1. ln-transformed AUC0-24 exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®

    The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed AUC0-24. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.

    Time frame: Days 1 and 24

  2. AEs, vital signs, ECG, laboratory tests

    all AEs, physical examinations, vital signs (heart rate, blood pressure, respiratory rate, and temperature), 12-lead ECGs, and laboratory safety tests (hematology, serum chemistry, coagulation, and urinalysis).

    Time frame: through study completion (14 days)

  3. ln-transformed Cavg of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®

    The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed Cavg. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.

    Time frame: Days 1 and 24

  4. ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®

    The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed Cmax,ss. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.

    Time frame: Days 1 and 24

07

Study locations

1 site
  • Celerion
    Neptune, New Jersey 07753, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2016
First posted
Aug 8, 2016
Start
Sep 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Aug 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02859129
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 8, 2016
Start date
Sep 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Aug 17, 2016

Study contacts

Michael D Davidson, MD
study director · Omthera Pharmaceuticals/AstraZeneca
Sandra M Connolly, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Omega-3 carboxylic acid

Start the discussion